Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax widely missed second-quarter forecasts Tuesday, leading the Covid vaccine maker to slash its guidance and NVAX stock to crash. The post Novavax Plummets: Covid Vaccine Sales Widely Lag On Unexpected Losses, Slashed Guidance appeared first on Investor's Business Daily.

Novavax Plummets: Covid Vaccine Sales Widely Lag On Unexpected Losses, Slashed Guidance

Novavax Inc. executives slashed their annual sales guidance in half on Monday while wildly missing financial expectations, sending shares down more than 30% in after-hours trading.

Novavax slashes sales guidance in half, stock plunges 30%

Novavax cut its 2022 sales outlook by about 50% and now expects to generate $2 billion to $2.3 billion in revenue this year.

Novavax cuts 2022 revenue guidance in half, stock tanks in after-hours trading

Novavax Inc on Monday cut its full-year revenue forecast after the company sold fewer doses of its COVID-19 vaccine in the second quarter.

Novavax cuts full-year revenue forecast as vaccine sales slow

Received FDA EUA and CDC recommendation for NVX-CoV2373, marking the first protein-based COVID-19 vaccine authorized in the U.S. for adults; with immunizations underway Nuvaxovid™ and Covovax™ authorized for adults in 43 countries, with booster authorizations in Japan, Australia and New Zealand as well as, adolescent authorizations in the EU, Australia, India, Japan, and Thailand Over 73 million doses delivered globally to date Progressing variant program with top-line clinical data for Omicron expected near the end of the third quarter of 2022 Adjusted revenue guidance to $2 billion to $2.3 billion Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md.

Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 3.05% to $58.43 Monday afternoon in sympathy with BioNTech SE - ADR (NASDAQ: BNTX), which reported worse-than-expected second-quarter results.

Why Novavax Stock Is Falling Monday

Novavax, Inc. (NASDAQ:NVAX) is not the usual meme stock akin to GameStop and AMC. However, it has often been at the center of retail investor interest at the slightest of the news.

Is Novavax's latest wins about to help it shed the meme tag when it reports earnings?

The daily average for new U.S. cases may have started to decline based on official numbers, but it's unclear at this time if the trend is real as so many people are testing at home and the data are not being captured.

Official U.S. new case tally may be declining but at-home testing obscures data, and Novavax starts trial of vaccine for very young children

GAITHERSBURG, Md. , Aug. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of its Phase 2b/3 Hummingbird™ global clinical trial.

Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years

BioNTech SE

Moderna

The booster market might be a long-term source of revenue.

Could the Fall Booster Market Boost Vaccine Stocks?

GAITHERSBURG, Md. , Aug. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2022 financial results and operational highlights on Monday, August 8, 2022, following the close of U.S. financial markets.

Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022

The biotech company got good news about its COVID-19 vaccine.

Why Novavax Stock Jumped on Tuesday

Novavax Inc. NVAX, +1.20% said Tuesday that its COVID-19 vaccine received authorization in Australia and Japan for teens. Both authorizations are for adolescents between the ages of 12 and 17 years old.

Novavax's COVID-19 vaccine is authorized for teens in Australia and Japan

Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan GAITHERSBURG, Md. , July 26, 2022  /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for primary immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md. , July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the Australian Therapeutic Goods Agency (TGA) has granted expanded approval for provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17

Novavax offers several clear advantages over its larger rival.

3 Reasons Why Novavax Is a Better Stock to Buy Than Moderna

OrthoPediatrics

 Pliant Therapeutics

Here's why we like Novavax, Orthopediatrics, and Pliant Therapeutics.

2022 Roundtable: Our Favorite Picks Right Now

The market has lost interest in the race for COVID-19 vaccines, perhaps understandably so.

Why Novavax Stock Is Down More Than 7% Today

Is Novavax stock a buy or a sell after the FDA authorized its Covid shot? Is NVAX stock a buy or a sell right now?

Novavax Wins FDA OK For Covid Shot, But Collapses — Is It A Buy Or A Sell?

Two years after the onset of COVID-19 in the U.S., a new vaccine is coming to market -- who will it help?

Is This Vaccine Stock a Buy After Big News?

Faraday Future Intelligent Electric

Palantir Technologies

Snap

Virgin Galactic

GEO Group

All meme stocks may not be sound investment options. A close scrutiny of these stocks can help to zero in on investment-worthy candidates from among these stocks.

7 Surprising Meme Stocks to Buy and Hold in 2022

The CDC's director signed off late Tuesday, making Novavax available to adults who haven't been vaccinated yet.

CDC Recommends Novavax, the 4th COVID Vaccine to Be Authorized

Novavax stock is up 6% today after the U.S. Centers for Disease Control and Prevention (CDC) approved its two-dose Covid-19 vaccine for use in adults. The post The CDC Just Gave Novavax (NVAX) Stock a Big Boost appeared first on InvestorPlace.

The CDC Just Gave Novavax (NVAX) Stock a Big Boost

Its vaccine might be more effective as a booster than the other options.

Here's How Novavax Stock Could Rally Through 2023

The Centers for Disease Control and Prevention endorsed a committee's recommendation that the Novavax COVID-19 vaccine be used as a primary series option for adults.

News for Novavax Stock (NVAX)